 WALTHAM, Mass., Nov. 04, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq: APLS, a global biopharmaceutical company and leader in complement, today announced that five abstracts were accepted for presentation at the American Society of Hematology ASH Annual Meeting to be held December 11-14, 2021. The new data further support the positive efficacy and safety profile of EMPAVELI, the first and only targeted C3 therapy, for the treatment of paroxysmal nocturnal hemoglobinuria PNH. 